EUVIMEDEUVIMED entdecken
Open Access

A gain-of-function variation in PLCG1 causes a new immune dysregulation disease

Panfeng Tao, Xu Han, Qintao Wang, Shihao Wang, Jiahui Zhang, Lin Liu, Xiaorui Fan, Chenlu Liu, Meng Liu, Li Guo, Pui Y Lee, Ivona Aksentijevich und 1 weitere

Journal of Allergy and Clinical Immunology · 2023-11 · 152 (5) · 1292-1302

DOI: 10.1016/j.jaci.2023.06.020 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Allergy and Clinical Immunology, 2023-11. Verfasst von Panfeng Tao und 12 weiteren Autor:innen. Beteiligte Einrichtung: Liangzhu Laboratory, Zhejiang University, Hangzhou, China; Life Sciences Institute, Zhejiang University, Hangzhou, China. Electronic address: taopanf…. Hauptthemen laut MEDLINE: NF-kappa B, Gain of Function Mutation. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Intramural NIH HHS, National Natural Science Foundation of China, China Postdoctoral Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Phospholipase C (PLC) γ1 is a critical enzyme regulating nuclear factor-κB (NF-κB), extracellular signal-related kinase, mitogen-activated protein kinase, and nuclear factor of activated T cells signaling pathways, yet germline PLCG1 mutation in human disease has not been reported. OBJECTIVE: We aimed to investigate the molecular pathogenesis of a PLCG1 activating variant in a patient with immune dysregulation. METHODS: Whole exome sequencing was used to identify the patient's pathogenic variants. Bulk RNA sequencing, single-cell RNA sequencing, quantitative PCR, cytometry by time of flight, immunoblotting, flow cytometry, luciferase assay, IP-One ELISA, calcium flux assay, and cytokine measurements in patient PBMCs and T cells and COS-7 and Jurkat cell lines were used to define inflammatory signatures and assess the impact of the PLCG1 variant on protein function and immune signaling. RESULTS: We identified a novel and de novo heterozygous PLCG1 variant, p.S1021F, in a patient presenting with early-onset immune dysregulation disease. We demonstrated that the S1021F variant is a gain-of-function variant, leading to increased inositol-1,4,5-trisphosphate production, intracellular Ca2+ release, and increased phosphorylation of extracellular signal-related kinase, p65, and p38. The transcriptome and protein expression at the single-cell level revealed exacerbated inflammatory responses in the patient's T cells and monocytes. The PLCG1 activating variant resulted in enhanced NF-κB and type II interferon pathways in T cells, and hyperactivated NF-κB and type I interferon pathways in monocytes. Treatment with either PLCγ1 inhibitor or Janus kinase inhibitor reversed the upregulated gene expression profile in vitro. CONCLUSIONS: Our study highlights the critical role of PLCγ1 in maintaining immune homeostasis. We illustrate immune dysregulation as a consequence of PLCγ1 activation and provide insight into therapeutic targeting of PLCγ1.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NF-kappa BGain of Function MutationHumansSignal TransductionMitogen-Activated Protein KinasesPhosphorylationPhospholipase C gamma

Stichwörter der Autor:innen

PLCG1autoinflammationgain-of-function variantimmune dysregulation

Substanzen

NF-kappa BMitogen-Activated Protein KinasesPLCG1 protein, humanPhospholipase C gamma

Autor:innen und Institutionen

  • Liangzhu Laboratory, Zhejiang University, Hangzhou, China; Life Sciences Institute, Zhejiang University, Hangzhou, China. Electronic address: taopanfeng@zju.edu.cn.
  • Life Sciences Institute, Zhejiang University, Hangzhou, China.
  • Liangzhu Laboratory, Zhejiang University, Hangzhou, China.
  • Life Sciences Institute, Zhejiang University, Hangzhou, China; Urology & Nephrology Center, Department of Nephrology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital, Hangzhou Medical College), Hangz…
  • Department of Rheumatology and Immunology, Guangdong Second Provincial General Hospital, Guangzhou, China.
  • Department of Rheumatology Immunology & Allergy, Children's Hospital, Zhejiang University School of Medicine, Hangzhou, China.

Förderung

  • Intramural NIH HHS
  • National Natural Science Foundation of China
  • China Postdoctoral Science Foundation

Zitieren

APA

Tao, P., Han, X., Wang, Q., Wang, S., Zhang, J., Liu, L., Fan, X., Liu, C., Liu, M., Guo, L., Lee, P. Y., Aksentijevich, I., & Zhou, Q. (2023). A gain-of-function variation in PLCG1 causes a new immune dysregulation disease. Journal of Allergy and Clinical Immunology, 152(5), 1292-1302. https://doi.org/10.1016/j.jaci.2023.06.020

Vancouver

Tao P, Han X, Wang Q, Wang S, Zhang J, Liu L, et al. A gain-of-function variation in PLCG1 causes a new immune dysregulation disease. Journal of Allergy and Clinical Immunology. 2023;152(5):1292-1302. doi:10.1016/j.jaci.2023.06.020

BibTeX
@article{Tao2023,
  author = {Tao, Panfeng and Han, Xu and Wang, Qintao and Wang, Shihao and Zhang, Jiahui and Liu, Lin and Fan, Xiaorui and Liu, Chenlu and Liu, Meng and Guo, Li and Lee, Pui Y and Aksentijevich, Ivona and Zhou, Qing},
  title = {A gain-of-function variation in PLCG1 causes a new immune dysregulation disease},
  journal = {Journal of Allergy and Clinical Immunology},
  year = {2023},
  volume = {152},
  number = {5},
  pages = {1292--1302},
  doi = {10.1016/j.jaci.2023.06.020}
}
Kostenlos starten →